Horan Capital Advisors LLC. reduced its stake in Mylan (NASDAQ:MYL) by 6.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 54,759 shares of the company’s stock after selling 3,929 shares during the period. Horan Capital Advisors LLC.’s holdings in Mylan were worth $2,317,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds also recently added to or reduced their stakes in MYL. Ameriprise Financial Inc. grew its stake in shares of Mylan by 4.0% in the 2nd quarter. Ameriprise Financial Inc. now owns 279,428 shares of the company’s stock valued at $10,844,000 after purchasing an additional 10,861 shares during the period. FMR LLC grew its stake in shares of Mylan by 19.8% in the 2nd quarter. FMR LLC now owns 813,267 shares of the company’s stock valued at $31,572,000 after purchasing an additional 134,258 shares during the period. Suntrust Banks Inc. grew its stake in shares of Mylan by 0.7% in the 2nd quarter. Suntrust Banks Inc. now owns 9,184 shares of the company’s stock valued at $355,000 after purchasing an additional 60 shares during the period. Stifel Financial Corp boosted its holdings in shares of Mylan by 1.2% in the 2nd quarter. Stifel Financial Corp now owns 59,480 shares of the company’s stock worth $2,310,000 after acquiring an additional 678 shares in the last quarter. Finally, AHL Partners LLP acquired a new position in shares of Mylan in the 2nd quarter worth approximately $1,353,000. Institutional investors own 75.00% of the company’s stock.
In other Mylan news, CEO Heather M. Bresch sold 75,000 shares of the company’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $45.00, for a total transaction of $3,375,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link. 0.69% of the stock is currently owned by corporate insiders.
Mylan (NASDAQ:MYL) last posted its quarterly earnings data on Monday, November 6th. The company reported $1.10 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by ($0.10). Mylan had a return on equity of 20.63% and a net margin of 7.28%. The firm had revenue of $2.99 billion for the quarter, compared to analyst estimates of $3.09 billion. During the same period in the prior year, the company posted $1.38 EPS. The firm’s quarterly revenue was down 2.3% compared to the same quarter last year. equities analysts expect that Mylan will post 4.55 earnings per share for the current year.
Several brokerages have recently commented on MYL. BidaskClub downgraded Mylan from a “buy” rating to a “hold” rating in a report on Saturday, February 3rd. Susquehanna Bancshares reissued a “positive” rating and issued a $55.00 target price (up from $47.00) on shares of Mylan in a report on Thursday, January 25th. Deutsche Bank set a $50.00 target price on Mylan and gave the stock a “buy” rating in a report on Wednesday, January 24th. Goldman Sachs Group boosted their target price on Mylan from $46.00 to $52.00 and gave the stock a “buy” rating in a report on Thursday, January 11th. Finally, Cantor Fitzgerald set a $34.00 target price on Mylan and gave the stock a “hold” rating in a report on Thursday, November 30th. One analyst has rated the stock with a sell rating, nine have given a hold rating and thirteen have issued a buy rating to the company’s stock. Mylan has an average rating of “Buy” and a consensus target price of $44.65.
COPYRIGHT VIOLATION WARNING: “Horan Capital Advisors LLC. Has $2.32 Million Stake in Mylan (MYL)” was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://www.com-unik.info/2018/02/08/horan-capital-advisors-llc-has-2-32-million-stake-in-mylan-myl.html.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan (NASDAQ:MYL).
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.